* FDA approves GlaxoSmithkline’s, XenoPort’s Horizant
NEW YORK, April 6 (Reuters) - GlaxoSmithKline Plc (GSK.L) and XenoPort Inc XNPT.O have received approval from the U.S. Food and Drug Administration for Horizant, a drug to treat restless legs syndrome, the companies said on Wednesday.
Horizant is the first drug in its class that the FDA has approved to treat moderate-to-severe primary restless legs syndrome, the companies said.
GlaxoSmithKline and XenoPort said the FDA approval came after two 12-week clinical trials in adults.
The FDA last year sought additional information from the companies on Horizant, after declining to approve it because of a potential link to cancer found in rats. (Reporting by Maria Aspan; editing by Carol Bishopric)